Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Cancer Prev Res (Phila). 2017 Jun 13;10(8):434–441. doi: 10.1158/1940-6207.CAPR-17-0100

Figure 1.

Figure 1

CONSORT diagram of subjects by eligibility for analysis and chemoprevention use. Abbreviations: AI=aromatase inhibitor; AH=atypical hyperplasia; BC=breast cancer; DCIS=ductal carcinoma in situ; ER=estrogen receptor; LCIS=lobular carcinoma in situ; PR=progesterone receptor; SERM=selective estrogen receptor modulator.